Best Peptides for Fat Loss 2026: Evidence-Based Rankings

Rankings reflect clinical evidence quality through 2026: number and size of randomized trials, magnitude of effect on body composition endpoints, regulatory approval status, and reproducibility across independent investigators. The ranking does not constitute medical advice and is not a recommendation for human use. Several compounds in this list are investigational or have no human approval for fat loss.

1. Tirzepatide (Mounjaro/Zepbound). Dual GIP/GLP-1 agonist. SURMOUNT-1 reported -22.5% mean weight loss at 15 mg over 72 weeks. SURMOUNT-5 demonstrated superiority over semaglutide in head-to-head obesity trial. The strongest body composition evidence base in 2026.

2. Semaglutide (Ozempic/Wegovy). Selective GLP-1 agonist. STEP 1 reported -14.9% weight loss at 2.4 mg over 68 weeks. SELECT trial added cardiovascular outcome data. The largest cumulative human exposure for any obesity peptide.

3. Retatrutide. Triple GIP/GLP-1/glucagon agonist (Lilly). Phase 2 reported -24.2% weight loss at 12 mg over 48 weeks, the largest mean reduction in any once-weekly peptide trial. Phase 3 TRIUMPH program ongoing in 2026. Investigational, no FDA approval.

4. Cagrilintide. Long-acting amylin analog. Phase 2 monotherapy ~-10.8% weight loss at 4.5 mg. Combined with semaglutide as CagriSema, REDEFINE Phase 3 results in 2024-2025 reported combined weight loss in the high teens. Investigational as monotherapy.

5. AOD-9604. Lipolytic GH fragment (residues 177-191 + Tyr). Animal models show beta-3 adrenergic and lipase activation. Multiple human obesity trials in the 2000s did not produce statistically meaningful weight loss versus placebo. Ranked here for completeness, not efficacy.

6. CJC-1295/Ipamorelin combination. Investigational GHRH analog plus selective GH secretagogue. The combination raises endogenous GH and IGF-1, with mechanistic plausibility for body composition effects. Direct fat-loss RCTs in humans are limited and the combination has no FDA approval. Often referenced in research peptide literature.

7. HGH Fragment 176-191. Synthetic fragment of human GH C-terminus. Preclinical lipolytic activity in adipocyte models. No large human obesity trials demonstrating fat-loss efficacy. Research interest persists, but evidence tier is below the GLP-1 class.

AOD-9604 is widely sold as a research peptide with marketing claims of selective fat loss. The published human evidence is older Phase 2 data showing no separation from placebo on weight endpoints. Ranking it 5 reflects mechanistic interest and easy availability for laboratory study, not clinical efficacy. Investigators citing AOD-9604 should reference the original GH fragment biology rather than relying on consumer-facing claims.

8. MOTS-c. A 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region. Animal models show improved insulin sensitivity and metabolic flexibility through AMPK activation. Human data are limited to small mechanistic studies. MOTS-c remains investigational with strong preclinical interest but minimal Phase 2 efficacy evidence on body weight as of 2026.

The fragment is structurally related to AOD-9604 with overlapping mechanistic claims. In rodent models it accelerates triglyceride mobilization without the anabolic effects of full-length GH. The translation to human clinically meaningful fat loss has not been established in randomized trials.

9. GHRP-2 (pralmorelin). A growth hormone secretagogue used historically as a diagnostic agent for GH deficiency. Mechanistic interest in body composition, but no FDA approval for fat loss. Listed because the compound appears frequently in peptide literature, not because RCT data support a fat-loss indication.

10. Tesamorelin (Egrifta). GHRH analog. FDA-approved 2010 for reduction of excess abdominal fat in HIV-associated lipodystrophy. Pivotal trials showed approximately 15% reduction in visceral adipose tissue at 26 weeks. Indication is narrow but the compound has the strongest regulatory evidence in this list outside the GLP-1 class for a specific fat distribution endpoint.

The 2026 evidence-based ranking is dominated by GLP-1 and multi-receptor incretins (positions 1-3), with cagrilintide as a near-Tier-1 amylin pathway entry. The GH-axis and mitochondrial peptides remain mechanistically interesting but evidence-thin for general fat loss. Tesamorelin is the regulatory-approved exception with a narrow visceral-fat indication. Investigators should prioritize compounds by indication-specific RCT data rather than by peptide class popularity.

• Read more: Retatrutide TRIUMPH-4 Phase 3 Data: 28.7% Body Weight Reduction → https://www.chemverify.com/learn/retatrutide-triumph-4-phase-3-28-percent-weight-loss
• Read more: Mounjaro vs Ozempic vs Wegovy: 2026 Complete Comparison Guide → https://www.chemverify.com/learn/mounjaro-vs-ozempic-vs-wegovy-2026-comparison
• Read more: Best Peptides for Muscle Growth 2026: What Research Actually Shows → https://www.chemverify.com/learn/best-peptides-for-muscle-growth-2026-research
• Read more: Ozempic Alternatives: 7 Verified Research Peptides Compared 2026 → https://www.chemverify.com/learn/ozempic-alternatives-7-verified-peptides-2026